{"created":"2015-05-18T17:49:20+00:00","modified":"2015-05-18T17:49:20+00:00","valid":{"from":"2014-06-24T10:00:00+00:00","to":"3014-06-24T10:00:00+00:00"},"hreflang":"en","guid":"af11906f-2bc7-4dd1-8ad3-1077dd8d3d98","itags":["Marketplace","Marketplace Morning Report","Marketplace Morning Report for Tuesday June 24, 2014","PMP:Marketplace_PMP","af11906f2bc7dd1dad3c1077dd8d3d98"],"byline":"Annie Baxter","contenttemplated":"[{\"content\":\"<p>Since the recession, U.S. employers&apos; health care spending growth has been slowing from year to year. That&apos;s about to change, according to a new report from PricewaterhouseCoopers’ Health Research Institute.</p>\",\"type\":\"text/html\"},{\"content\":\"<p><span>The report says employer health care spending will accelerate in 2015, rising by 6.8 percent, a slightly faster rate of growth than what the company projected for 2014. The report’s authors say expensive specialty drugs will play a role in fueling the sharper rise in spending.</span></p>\",\"type\":\"text/html\"},{\"content\":\"<p><span>&quot;It&apos;s actually a very big deal in terms of dollars. It&apos;s one of the reasons we single out that factor for 2015,” says Ceci Connolly, managing director of PricewaterhouseCooper’s Health Research Institute.</span></p>\",\"type\":\"text/html\"},{\"content\":\"<p><span>Connolly points to a new treatment for Hepatitis C as an example of the new, high-cost drugs. Hepatitis C is a virus that causes liver disease and affects about 3 million Americans. One breakthrough drug, Sovaldi, can completely cure Hepatitis C in a high percentage of patients. But a twelve-week treatment costs $84,000.</span></p>\",\"type\":\"text/html\"},{\"content\":\"<p><span>However, in the case of Hepatitis C drugs, the hit to employers might not last long, according to Princeton University health care economist Uwe Reinhardt.</span></p>\",\"type\":\"text/html\"},{\"type\":\"text/html\",\"content\":\"<p><span>“Eventually all the people with Hep C will be cured, and all you have to do is deal with the new ones, which is not that heavy a growth,” he says.</span></p>\"},{\"type\":\"text/html\",\"content\":\"<p><span>The PricewaterhouseCoopers researchers say that in the short-term, employers will probably try to offset higher medical costs by shifting more of them to workers.</span></p>\"}]","published":"2014-06-24T10:00:00+00:00","description":"Why health care spending is projected to accelerate in 2015.","teaser":"Why health care spending is projected to accelerate in 2015.","tags":["APM","Health Care","health care costs","medicine"],"contentencoded":"<div class=\"barn-cleaned\"><p>Since the recession, U.S. employers' health care spending growth has been slowing from year to year. That's about to change, according to a new report from PricewaterhouseCoopers’ Health Research Institute.</p>\n<p><span>The report says employer health care spending will accelerate in 2015, rising by 6.8 percent, a slightly faster rate of growth than what the company projected for 2014. The report’s authors say expensive specialty drugs will play a role in fueling the sharper rise in spending.</span></p>\n<p><span>\"It's actually a very big deal in terms of dollars. It's one of the reasons we single out that factor for 2015,” says Ceci Connolly, managing director of PricewaterhouseCooper’s Health Research Institute.</span></p>\n<p><span>Connolly points to a new treatment for Hepatitis C as an example of the new, high-cost drugs. Hepatitis C is a virus that causes liver disease and affects about 3 million Americans. One breakthrough drug, Sovaldi, can completely cure Hepatitis C in a high percentage of patients. But a twelve-week treatment costs $84,000.</span></p>\n<p><span>However, in the case of Hepatitis C drugs, the hit to employers might not last long, according to Princeton University health care economist Uwe Reinhardt.</span></p>\n<p><span>“Eventually all the people with Hep C will be cured, and all you have to do is deal with the new ones, which is not that heavy a growth,” he says.</span></p>\n<p><span>The PricewaterhouseCoopers researchers say that in the short-term, employers will probably try to offset higher medical costs by shifting more of them to workers.</span></p></div>","title":"Specialty drugs could fuel health care inflation","audio":[{"type":"image/jpeg","meta":{"width":"610","height":"340","crop":"primary"},"href":"http://www.marketplace.org/sites/default/files/styles/primary-image-610x340/public/495314721_1.jpg?itok=VydT6ykK"},{"meta":{"duration_hms":"00:01:21","api":{"type":"application/json","href":"http://api.publicradio.org/audio/v2?ref=pmp&id=apm-audio:/marketplace/segments/2014/06/24/marketplace_segment04_20140624"},"duration":81},"href":"http://play.publicradio.org/pmp/d/podcast/marketplace/segments/2014/06/24/marketplace_segment04_20140624_64.mp3","format":"MP3","type":"audio/mpeg"}]}